Gareth Soloway's technical market breakdown: S&P 500 trend-line test, semiconductor unwind, AI-to-biotech rotation, USD/JPY ...

Biotech is having a moment, and the numbers are hard to ignore. The SPDR S&P Biotech ETF (NYSEARCA:XBI) climbed 17.27% over ...

Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological ...

Biopharmaceutical developers should introduce risk-based, phase-appropriate characterization strategies for quality control ...

Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant ...

Morgan Stanley says U.S. equity-market leadership is beginning to expand beyond the semiconductor and AI infrastructure ...

Morgan Stanley’s pivot is from “chip winners” to hyperscalers with AI infrastructure optionality. MSFT has the strongest mix ...

Hospitals and health systems are rapidly adopting AI-powered tools, connected medical devices, advanced analytics and emerging biotechnology solutions. Most organizations evaluate these technologies ...

(NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 and FLT3 inhibitor, today announced an important enrollment ...

Modern biopharma firms are adapting their R&D investment strategies in response to challenges such as the impending $300 ...

Genmab A/S(Nasdaq: GMAB) announced today that the European Commission (EC) granted marketing authorization for TEPKINLY ® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R 2 ) ...

Elicio Therapeutics, Inc. (Nasdaq: ELTX) ('Elicio” or the 'Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced the ...